A carregar...
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
BACKGROUND: This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples of advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and whether baseline cPD-L1 levels were assoc...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5915137/ https://ncbi.nlm.nih.gov/pubmed/29707129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24785 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|